Skip to main content
LONA
NASDAQ Life Sciences

LeonaBio Reaches 500th Patient in Phase 3 ELAINE-3, Opening $146M Warrant Exercise Window

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.01
Mkt Cap
$75.468M
52W Low
$3.6
52W High
$40.8
52W Position info
123% above low
Off High info
80% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

LONA has more than doubled off its 52-week low of $3.6 on light trading volume (0.3× avg).

Summary

LeonaBio enrolled the 500th patient in its Phase 3 ELAINE-3 trial, triggering exercisability of 23M Series A warrants that could bring up to $146.2M in capital.


Key Events · Product Development and Regulatory · LONA

  • 500th Patient Enrolled in ELAINE-3

    LeonaBio enrolled the 500th subject in its Phase 3 ELAINE-3 trial for lasofoxifene plus abemaciclib in ESR1-mutated metastatic breast cancer.

  • Warrant Exercise Triggered

    The enrollment milestone triggers exercisability of 23,031,494 Series A Common Warrants at $6.35 per share, issued in the December 2025 private placement.

  • Potential $146.2M Capital Inflow

    If exercised in full, the warrants would provide approximately $146.2 million in additional capital, versus $51.1 million cash on hand as of Q2 2026.

  • Exercise Window Through November 30, 2026

    Warrants are exercisable at holders' option until the 30th day after the Initial Exercise Date, with a termination date no later than November 30, 2026.


Analysis · LONA · Life Sciences

Enrollment of the 500th subject in the pivotal Phase 3 ELAINE-3 trial for lasofoxifene in ESR1-mutated metastatic breast cancer marks more than clinical progress. It triggers exercisability of 23,031,494 Series A Common Warrants issued in the December 2025 private placement. If exercised in full at $6.35 per share, the warrants would bring approximately $146.2 million in additional capital—a substantial sum relative to the company's $51.1 million cash balance disclosed in the Q2 10-Q. The warrant exercise window opens now and runs through no later than November 30, 2026. Against a going concern warning, this milestone offers a potential financing lifeline, though exercise is at holders' option and may be cashless if a resale registration statement is unavailable.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LONA was trading at $8.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.5M. The 52-week trading range was $3.60 to $40.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LONA - Latest Insights

LONA
Nov 16, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $3.23
Real-time Price: $2.59 info
Change: -$0.640 (-20%) info
Market Cap: $33.868M info
LONA
Nov 16, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.23
Real-time Price: $2.59 info
Change: -$0.640 (-20%) info
Market Cap: $33.868M info
LONA
Sep 22, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.05
Real-time Price: $2.59 info
Change: -$3.46 (-57%) info
Market Cap: $33.868M info
LONA
Aug 31, 2026, 4:31 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $7.92
Real-time Price: $2.59 info
Change: -$5.33 (-67%) info
Market Cap: $33.868M info
LONA
Aug 14, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.97
Real-time Price: $2.59 info
Change: -$5.38 (-67%) info
Market Cap: $33.868M info